Symphogen AS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Symphogen AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013278
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics to enhance the lives of patients with cancer and other diseases with significant unmet medical needs. Its product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), glioblastoma (GBM), solid tumor malignancies and MET-amplified solid tumors and partner targets. It has collaborations for the development of antibody therapeutics in immuno-oncology with Shire and infectious disease area with Genentech. Symphogen has offices in Denmark and New Jersey, the US.

Symphogen AS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Symphogen A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Symphogen A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Symphogen A/S, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Symphogen Raises USD76.6 Million in Venture Financing 10
Symphogen Raises US$54 Million In Expanded Venture Financing Round 11
SYMPHOGEN Raises US$132 Million In Venture Financing 12
Partnerships 13
Baxalta Enters into Agreement with Symphogen 13
Symphogen Enters Into Agreement With Open Monoclonal Technology 14
Equity Offering 15
Symphogen Plans IPO 15
Symphogen A/S – Key Competitors 16
Symphogen A/S – Key Employees 17
Symphogen A/S – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Corporate Communications 19
Sep 14, 2016: Symphogen Names New Chief Financial Officer 19
Aug 18, 2016: Symphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director 20
Clinical Trials 21
Apr 12, 2016: Symphogen Initiates Anti-MET Clinical Program and Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Symphogen A/S, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Symphogen A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Symphogen A/S, Deals By Therapy Area, 2011 to YTD 2017 8
Symphogen A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Symphogen Raises USD76.6 Million in Venture Financing 10
Symphogen Raises US$54 Million In Expanded Venture Financing Round 11
SYMPHOGEN Raises US$132 Million In Venture Financing 12
Baxalta Enters into Agreement with Symphogen 13
Symphogen Enters Into Agreement With Open Monoclonal Technology 14
Symphogen Plans IPO 15
Symphogen A/S, Key Competitors 16
Symphogen A/S, Key Employees 17
Symphogen A/S, Subsidiaries 18

★海外企業調査レポート[Symphogen AS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Halliburton Co (HAL):企業の財務・戦略的SWOT分析
    Halliburton Co (HAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • GE Healthcare LLC:医療機器:M&Aディール及び事業提携情報
    Summary GE Healthcare LLC (GE Healthcare) a business unit of General Electric Company, is a global medical device provider that designs, develops, manufactures, and distributes diagnostic imaging and clinical systems; products and services for drug discovery, biopharmaceutical manufacturing and cell …
  • Talktalk Telecom Group PLC (TALK):企業の戦略的SWOT分析
    Talktalk Telecom Group PLC (TALK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • TOTAL S.A.:企業の戦略・SWOT・財務情報
    TOTAL S.A. - Strategy, SWOT and Corporate Finance Report Summary TOTAL S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • BRT Apartments Corp.:企業の戦略・SWOT・財務情報
    BRT Apartments Corp. - Strategy, SWOT and Corporate Finance Report Summary BRT Apartments Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Excision BioTherapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Excision BioTherapeutics Inc (Excision BioTherapeutics) is a developer of gene editing therapeutics for the treatment of infectious diseases. The company’s products comprise EBT101, a HIV CRISPR Cas9 gRNA multiplex biologic for the prevention of Human Immunodeficiency Virus; EBT103, a PML JC …
  • Emera Inc (EMA):電力:M&Aディール及び事業提携情報
    Summary Emera Inc (Emera) is an energy and services company. It invests in electricity, natural gas and utility energy services. Through ownership and equity investments in various companies, Emera generates, transmits and distributes electricity; procures, transmits and distributes natural gas; mar …
  • Qube Holdings Ltd:戦略・SWOT・企業財務分析
    Qube Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Qube Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Apollo Education Group, Inc.:企業の戦略・SWOT・財務情報
    Apollo Education Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Apollo Education Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Pro-Pac Packaging Ltd (PPG):企業の財務・戦略的SWOT分析
    Pro-Pac Packaging Ltd (PPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bancolombia S.A.:企業の戦略・SWOT・財務分析
    Bancolombia S.A. - Strategy, SWOT and Corporate Finance Report Summary Bancolombia S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Toma Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Toma Biosciences Inc (Toma Biosciences) is a biotechnology company that provides genome sequencing solutions. The company launched TOMA OS-Seq cancer assay to laboratories and researchers for the changes in tumors. Its products include reagent kits developed to detect genomic changes in canc …
  • Electricidade de Mocambique EP-エネルギー分野:企業M&A・提携分析
    Summary Electricidade de Mocambique EP (EDM) is a state owned vertically integrated energy utility that generates, distributes, transmits, and commercializes electricity. The company produces electricity from hydro and thermal sources. It has interests in Lichinga, Cuamba, Corumana, Chicamba, and Ma …
  • Bioxyne Ltd (BXN):企業の財務・戦略的SWOT分析
    Bioxyne Ltd (BXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Lavendon Group Plc:企業の戦略・SWOT・財務情報
    Lavendon Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lavendon Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Aurora Spine Corp (ASG):企業の財務・戦略的SWOT分析
    Summary Aurora Spine Corp (Aurora) is a medical equipment provider that offers surgical tools. The company offers novel solutions in the spinal implant market through a range of minimally invasive, and regenerative spinal implant technologies. It develops and distributes spinal implant products whic …
  • Banco Hipotecario SA (BHIP3):企業の財務・戦略的SWOT分析
    Banco Hipotecario SA (BHIP3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • RPS Group Plc (RPS):企業の財務・戦略的SWOT分析
    RPS Group Plc (RPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Vivus Inc (VVUS):企業の財務・戦略的SWOT分析
    Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • GROUPE ADEO SA:戦略・SWOT・企業財務分析
    GROUPE ADEO SA - Strategy, SWOT and Corporate Finance Report Summary GROUPE ADEO SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆